| 42.25 -0.18 (-0.42%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.12 | 1-year : | 63.06 |
| Resists | First : | 48.9 | Second : | 53.99 |
| Pivot price | 43.99 |
|||
| Supports | First : | 40.68 | Second : | 33.84 |
| MAs | MA(5) : | 42.22 | MA(20) : | 44.9 |
| MA(100) : | 52.91 |
MA(250) : | 48.7  |
|
| MACD | MACD : | -2 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 27 |
D(3) : | 22 |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 64.98 | Low : | 20.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MLTX ] has closed above bottom band by 26.6%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.74 - 42.98 | 42.98 - 43.24 |
| Low: | 40.53 - 40.79 | 40.79 - 41.08 |
| Close: | 41.74 - 42.21 | 42.21 - 42.72 |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Tue, 23 Apr 2024
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Fri, 19 Apr 2024
Federated Hermes Inc. Has $64.05 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Wed, 10 Apr 2024
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research ... - Business Wire
Tue, 02 Apr 2024
Goldman starts MoonLake at neutral, cites lead drug potential (NASDAQ:MLTX) - Seeking Alpha
Fri, 15 Mar 2024
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business - Yahoo Finance
Mon, 11 Mar 2024
MoonLake Immunotherapeutics Unveils Psoriatic Arthritis Breakthroughs - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 7,650 (K) |
| Shares Short P.Month | 6,940 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.3 % |
| Return on Equity (ttm) | -15.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -57.88 |
| PEG Ratio | 0 |
| Price to Book value | 5.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -62.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|